Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term Experience With Abatacept SC in Routine Clinical Practice

Trial Profile

Long-term Experience With Abatacept SC in Routine Clinical Practice

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASCORE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Jun 2019 Interim results of Ascore trial assessing abatacept for the treatment of rheumatoid arthritis presented at the 20th Annual Congress of the European League Against Rheumatism
    • 13 Nov 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
    • 13 Nov 2018 Planned primary completion date changed from 31 Dec 2018 to 30 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top